News & Events
BD Signs Agreement for Installation of the BD Cato™ Workflow Solution in Leading Cancer Center
First Healthcare Institution in the U.S. to Implement the System
Franklin Lakes, NJ () –
BD Medical, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced an agreement with The University of Texas MD Anderson Cancer Center for BD Cato™, a system that enhances safety and workflow efficiency in medication preparation via gravimetric and barcoding technology. MD Anderson Cancer Center will be the first healthcare institution in the U.S. to implement the BD Cato System and will be incorporating the system into its outpatient infusion pharmacies, including community-based locations.
“We are pleased to provide MD Anderson Cancer Center with the BD Cato system and the increased assurance that the right patient is receiving the right medication in the right dose,” said William A. Tozzi, President, BD Medical – Medical Surgical Systems. “Medication errors are one of the top concerns on the minds of healthcare providers today and the BD Cato system offers a significant step forward in improving safety and patient outcomes, while also optimizing workflow efficiencies.”
BD Cato Workflow Solution provides an automated system that creates and shares data to reduce the possibility of human error, standardize practice, streamline workflow and increase efficiency from medication preparation to delivery in the pharmacy. The software detects potential medication errors and associated costs, automates documentation, and optimizes drug utilization to reduce drug waste. The system interfaces with Pharmacy IT systems to pull in physician orders and allow dose queue management within the preparation environment, thereby simultaneously improving safety and efficiency.
BD is a leading medical technology company that partners with customers and stakeholders to address many of the world’s most pressing and evolving health needs. Our innovative solutions are focused on improving drug delivery, enhancing the diagnosis of infectious diseases and cancers, supporting the management of diabetes and advancing cellular research. We are nearly 30,000 associates in 50 countries who strive to fulfill our purpose of “Helping all people live healthy lives”
by advancing the quality, accessibility, safety and affordability of healthcare around the world. For more information, please visit www.bd.com